ArticleTransfusion2026
Administration of 25% albumin improves prehospital survivability in a preclinical rat model of decompensated hemorrhagic shock.
Article in Transfusion, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundPlasma has been used as an efficient resuscitation fluid to improve prehospital survival from hemorrhagic shock. The 25% albumin (25% ALB, w/v in aqueous diluent) is a hyperoncotic fluid, and we hypothesize that it can be used as a lower-volume alternative to plasma in hypovolemic shock.
methodIsoflurane-anesthetized Sprague-Dawley rats were subjected to a lethal decompensated hemorrhagic shock via removing 65% estimated blood volume (EBV, calculated by 6% body weight (gram) + 0.77 mL) of blood within 20 min. At 20 min post-hemorrhage, rats randomly received plasma (20% EBV), 25% ALB (4% EBV), or respective vehicles, followed by fresh whole blood (FWB, 20% EBV) at 1 h post-hemorrhage. The outcome was also compared between plasma and 25% ALB without FWB resuscitation in a separate experiment.
results20% EBV of plasma or 4% EBV of 25% ALB led to 100% survival at 60 min from the start of hemorrhage, compared to zero survival without treatment. Survival was maintained at least 4 h following limited resuscitation, with or without FWB at 1 h post-hemorrhage. The lack of fibrinogen in 25% ALB was notable and compromised the hemostatic outcome as compared to using plasma, which was partially restored by FWB resuscitation with the reduction in prothrombin time.
conclusionThe current study indicates that 25% ALB enhances survival and maintains hemodynamics at only one-fifth the volume of plasma. The results also suggest that 25% ALB requires hemostatic agents or subsequent blood products to counteract the hemostatic deficiency caused by hemodilution.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.